Replies to post #252269 on Biotech Values

[Mufaso]

Private company developing oral glucose for pre-diabetes:

Dew- The trial you referenced met it's endpoint of "proves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration". I find this interesting as company has a trial for this same drug focused on obesity. (you referenced this in #msg-174303880)

Glucose is a carbohydrate and Aphaia's oral approach is interesting. From their website:

Aphaia’s lead drug candidate is a proprietary oral formulation of coated glucose beads. It is designed to be released at discrete parts of the small intestine to reawaken nutrient-sensing cells that become less responsive in obesity and restore endocrine, neuroendocrine and neuronal signaling pathways.

By design of the beads, the glucose released from the formulation is not absorbed in the upper parts of the small intestine and is not systemically available, which is a key safety feature in general, but particularly in diabetic patients.

Aphaia selected glucose as its drug formulation for two key reasons. Firstly, its natural composition suggests a safer profile. Secondly, glucose maximizes nutrient-sensing cell responses, whereas other compounds may trigger insufficient or delayed hormone releases.